Decay-accelerating factor but not CD59 limits experimental immune-complex glomerulonephritis

Laboratory Investigation

Volumn 87, Issue 4, 2007, Pages 357-364

  Bao, Lihua ^a   Haas, Mark ^b   Minto, Andrew W ^a   Quigg, Richard J ^a  

^a UNIVERSITY OF CHICAGO   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CD59; Complement; Decay accelerating factor; Glomerulonephritis; Immune complex

Indexed keywords

APOFERRITIN; CD45 ANTIGEN; CD59 ANTIGEN; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C5B; DECAY ACCELERATING FACTOR; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 1; PROTEIN; PROTEIN DAF; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL INFILTRATION; COMPLEMENT DEPOSITION; CONTROL GROUP; CONTROLLED STUDY; GLOMERULUS; IMMUNE COMPLEX NEPHRITIS; IMMUNIZATION; INCIDENCE; LEUKOCYTE; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN DEFICIENCY; WILD TYPE;

ANIMALS; ANTIGENS, CD45; ANTIGENS, CD55; ANTIGENS, CD59; APOFERRITINS; BLOOD UREA NITROGEN; CHEMOKINE CCL2; CHRONIC DISEASE; COMPLEMENT ACTIVATION; COMPLEMENT C3; COMPLEMENT C5A; COMPLEMENT MEMBRANE ATTACK COMPLEX; DISEASE MODELS, ANIMAL; GLOMERULONEPHRITIS; HORSES; KIDNEY GLOMERULUS; LEUKOCYTES; MICE; MICE, KNOCKOUT; SERUM SICKNESS;

EID: 33947497027     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.3700522     Document Type: Article

References (62)

1. Walport MJ. Advances in immunology: complement (first of two parts). N Engl J Med 2001;344:1058-1066.
2. Liszewski MK, Atkinson JP. The complement system. In: Paul WE (eds). Fundamental Immunology, vol 3. Raven Press: New York, 1993, pp 917-939.
3. Harris CL, Rushmere NK, Morgan BP. Molecular and functional analysis of mouse decay accelerating factor (CD55). Biochem J 1999;341(Pt 3):821-829.
4. Nicholson-Weller A, Wang C. Structure and function of decay accelerating factor CD55. J Lab Clin Med 1994;123:485-491.
5. Davies A, Lachmann PJ. Membrane defence against complement lysis: The structure and biological properties of CD59. Immunol Res 1993;12:258-275.
6. Quigg RJ. Complement and autoimmune glomerular diseases. Curr Dir Autoimmun 2004;7:165-180.
7. Stilmant MM, Couser WG, Cotran RS. Experimental glomerulonephritis in the mouse associated with mesangial deposition of autologous ferritin immune complexes. Lab Invest 1975;32:746-756.
8. Iskandar SS, Gifford DR, Emancipator SN. Immune complex acute necrotizing glomerulonephritis with progression to diffuse glomerulosclerosis. A murine model. Lab Invest 1988;59:772-779.
9. Falk RJ, Jennette JC. Immune complex induced glomerular lesions in C5 sufficient and deficient mice. Kidney Int 1986;30:678-686.
10. Alexander JJ, Pickering MC, Haas M, et al. Complement factor H limits immune complex deposition and prevents inflammation and scarring in glomeruli of mice with chronic serum sickness. J Am Soc Nephrol 2005;16:52-57.
11. Quigg RJ, Lim A, Haas M, et al. Immune complex glomerulonephritis in C4- and C3-deficient mice. Kidney Int 1998;53:320-330.
12. Welch TR, Frenzke M, Witte D, et al. C5a is important in the tubulointerstitial component of experimental immune complex glomerulonephritis. Clin Exp Immunol 2002;13:43-48.
13. Miwa T, Zhou L, Hilliard B, et al. Crry, but not CD59 and DAF, is indispensable for murine erythrocyte protection in vivo from spontaneous complement attack. Blood 2002;99:3707-3716.
14. Sogabe H, Nangaku M, Ishibashi Y, et al. Increased susceptibility of decay-accelerating factor deficient mice to anti-glomerular basement membrane glomerulonephritis. J Immunol 2001;167:2791-2797.
15. Miwa T, Sun X, Ohta R, et al. Characterization of glycosylphosphatidylinositol-anchored decay accelerating factor (GPIDAF) and transmembrane DAF gene expression in wild-type and GPIDAF gene knockout mice using polyclonal and monoclonal antibodies with dual or single specificity. Immunology 2001;104:207-214.
16. Bao L, Osawe I, Haas M, et al. Signaling through up-regulated C3a receptor is key to the development of experimental lupus nephritis. J Immunol 2005;175:1602-1610.
17. Bao L, Zhou J, Holers VM, et al. Excessive matrix accumulation in the kidneys of MRL/lpr lupus mice is dependent on complement activation. J Am Soc Nephrol 2003;14:2516-2525.
18. Anders HJ, Vielhauer V, Schlondorff D. Chemokines and chemokine receptors are involved in the resolution or progression of renal disease. Kidney Int 2003;63:401-415.
19. Bao L, Osawe I, Puri T, et al. C5a promotes development of experimental lupus nephritis which can be blocked with a specific receptor antagonist. Eur J Immunol 2005;35:3012-3020.
20. Tang T, Rosenkranz A, Assmann KM, et al. A role for Mac-1 (CDIIb/ CD18) in immune complex-stimulated neutrophil function in vivo: Mac-1 deficiency abrogates sustained Fcgamma receptor-dependent neutrophil adhesion and complement-dependent proteinuria in acute glomerulonephritis. J Exp Med 1997;186:1853-1863.
21. Braun MC, Reins RY, Li TB, et al. Renal expression of the C3a receptor and functional responses of primary human proximal tubular epithelial cells. J Immunol 2004;173:4190-4196.
22. Fayyazi A, Scheel O, Werfel T, et al. The C5a receptor is expressed in normal renal proximal tubular but not in normal pulmonary or hepatic epithelial cells. Immunology 2000;99:38-45.
23. Zahedi R, Braun M, Wetsel RA, et al. The C5a receptor is expressed by human renal proximal tubular epithelial cells. Clin Exp Immunol 2000;121:226-233.
24. Braun M, Davis III AE. Cultured human glomerular mesangial cells express the C5a receptor. Kidney Int 1998;54:1542-1549.
25. Wilmer WA, Kaumaya PT, Ember JA, et al. Receptors for the anaphylatoxin C5a (CD88) on human mesangial cells. J Immunol 1998;160:5646-5652.
26. Shushakova N, Tkachuk N, Dangers M, et al. Urokinase-induced activation of the gp130/Tyk2/Stat3 pathway mediates a proinflammatory effect in human mesangial cells via expression of the anaphylatoxin C5a receptor. J Cell Sci 2005;118:2743-2753.
27. Wenderfer SE, Ke B, Hollmann TJ, et al. C5a receptor deficiency attenuates T cell function and renal disease in MRLlpr mice. J Am Soc Nephrol 2005;16:3572-3582.
28. Perianayagam MC, Madias NE, Pereira BJ, et al. CREB transcription factor modulates Bcl2 transcription in response to C5a in HL-60-derived neutrophils. Eur J Clin Invest 2006;36:353-361.
29. Guo RF, Ward PA. Role of C5a in inflammatory responses. Annu Rev Immunol 2005;23:821-852.
30. Strey CW, Markiewski M, Mastellos D, et al. The proinflammatory mediators C3a and C5a are essential for liver regeneration. J Exp Med 2003;198:913-923.
31. Laudes IJ, Chu JC, Huber-Lang M, et al. Expression and function of C5a receptor in mouse microvascular endothelial cells. J Immunol 2002;169:5962-5970.
32. Quigg RJ. Complement and the kidney. J Immunol 2003;171:3319-3324.
33. Spicer AP, Seldin MF, Gendler SJ. Molecular cloning and chromosomal localization of the mouse decay-accelerating factor genes. J Immunol 1995;155:3079-3091.
34. Powell MB, Marchbank KJ, Rushmere NK, et al. Molecular cloning, chromosomal localization, expression, and functional characterization of the mouse analogue of human CD59. J Immunol 1997;158:1692-1702.
35. Song WC, Deng C, Raszmann K, et al. Mouse decay-accelerating factor: selective and tissue-specific induction by estrogen of the gene encoding the glycosylphosphatidylinositol-anchored form. J Immunol 1996;157:4166-4172.
36. Cosio FG, Sedmak DD, Mahan JD, et al. Localization of decay accelerating factor in normal and diseased kidneys. Kidney Int 1989;36:100-107.
37. Abe K, Miyazaki M, Koji T, et al. Expression of decay accelerating factor mRNA and complement C3 mRNA in human diseased kidney. Kidney Int 1998;54:120-130.
38. Tamai H, Matsuo S, Fukatsu A, et al. Localization of 20-kD homologous restriction factor (HRF20) in diseased human glomeruli. An immunofluorescence study. Clin Exp Immunol 1991;84:256-262.
39. Cosio FG, Shibata T, Rovin BH, et al. Effects of complement activation products on the synthesis of decay accelerating factor and membrane cofactor protein by human mesangial cells. Kidney Int 1994;46:986-992.
40. Bao L, Spiller OB, St JP, et al. Decay-accelerating factor expression in the rat kidney is restricted to the apical surface of podocytes. Kidney Int 2002;62:2010-2021.
41. Ichida S, Yuzawa Y, Okada H, et al. Localization of the complement regulatory proteins in the normal human kidney. Kidney Int 1994;46:89-96.
42. Funabashi K, Okada N, Matsuo S, et al. Tissue distribution of complement regulatory membrane proteins in rats. Immunology 1994;81:444-451.
43. Quigg RJ, Holers VM, Morgan BP, et al. Crry and CD59 regulate complement in rat glomerular epithelial cells and are inhibited by the nephritogenic antibody of passive Heymann nephritis. J Immunol 1995;154:3437-3443.
44. Quigg RJ, Morgan BP, Holers VM, et al. Complement regulation in the rat glomerulus: Crry and CD59 regulate complement in glomerular mesangial and endothelial cells. Kidney Int 1995;48:412-421.
45. Matsuo S, Nishikage H, Yoshida F, et al. Role of CD59 in experimental glomerulonephritis in rats. Kidney Int 1994;46:191-200.
46. Cunningham PN, Hack BK, Ren G, et al. Glomerular complement regulation is overwhelmed in passive Heymann nephritis. Kidney Int 2001;60:900-909.
47. Chugh S, Yuan H, Topham PS, et al. Aminopeptidase A: a nephritogenic target antigen of nephrotoxic serum. Kidney Int 2001;59:601-613.
48. Lin F, Emancipator SN, Salant DJ, et al. Decay-accelerating factor confers protection against complement-mediated podocyte injury in acute nephrotoxic nephritis. Lab Invest 2002;82:563-569.
49. Turnberg D, Botto M, Warren J, et al. CD59a deficiency exacerbates accelerated nephrotoxic nephritis in mice. J Am Soc Nephrol 2003;14:2271-2279.
50. Lin F, Salant DJ, Meyerson H, et al. Respective roles of decay-accelerating factor and CD59 in circumventing glomerular injury in acute nephrotoxic serum nephritis. J Immunol 2004;172:2636-2642.
51. Wong W, Fearon DT. p65: a C3b-binding protein on murine cells that shares antigenic determinants with the human C3b receptor (CR1) and is distinct from murine C3b receptor. J Immunol 1985;134:4048-4056.
52. Takizawa H, Okada N, Okada H. Complement inhibitor of rat cell membrane resembling mouse Crry/p65. J Immunol 1994;152:3032-3038.
53. Paul MS, Aegerter M, O'Brien SE, et al. The murine complement receptor gene family. I. Analysis of mCRY gene products and their homology to human CR1. J Immunol 1989;142:582-589.
54. Kim Y-U, Kinoshita T, Molina H, et al. Mouse complement regulatory protein Crry/p65 uses the specific mechanisms of both human decay-accelerating factor and membrane cofactor protein. J Exp Med 1995;181:151-159.
55. Li B, Sallee C, Dehoff M, et al. Mouse Crry/p65: characterization of monoclonal antibodies and the tissue distribution of a functional homologue of human MCP and DAF. J Immunol 1993;151:4295-4305.
56. Johnson RJ, Hillmen P. Paroxysmal nocturnal haemoglobinuria: Nature's gene therapy? Mol Pathol 2002;55:145-152.
57. Nishikage H, Baranyi L, Okada H, et al. Role of a complement regulatory protein in rat mesangial glomerulonephritis. J Am Soc Nephrol 1995;6:234-242.
58. Xu C, Mao D, Holers VM, et al. A critical role for murine complement regulator Crry in fetomaternal tolerance. Science 2000;287:498-501.
59. Ault BH, Schmidt BZ, Fowler NL, et al. Human factor H deficiency. Mutations in framework cysteine residues and block in H protein secretion and intracellular catabolism. J Biol Chem 1997;272:25168-25175.
60. Hegasy GA, Manuelian T, Hogasen K, et al. The molecular basis for hereditary porcine membranoproliferative glomerulonephritis type II: point mutations in the factor H coding sequence block protein secretion. Am J Pathol 2002;161:2027-2034.
61. Pickering MC, Cook HT, Warren J, et al. Uncontrolled C3 activation causes membranoproliferative glomerulonephritis in mice deficient in complement factor H. Nat Genet 2002;31:424-428.
62. Alexander JJ, Aneziokoro OGB, Chang A, et al. Distinct and separable roles of the complement system in factor H-deficient bone marrow chimeric mice with immune complex disease. J Am Soc Nephrol 2006;17:1354-1361.